Stock BIO3 BIOTEST AG
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Biotest AG Deutsche Boerse AG

Equities

BIO3

DE0005227235

Real-time Estimate Tradegate
Other stock markets
 09:30:00 2024-04-29 am EDT 		5-day change 1st Jan Change
28.8 EUR +1.05% Intraday chart for Biotest AG +0.35% -7.47%
Apr. 19 Biotest Launches New Plasma Collection Center in Germany MT
Mar. 28 Biotest Aktiengesellschaft Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The company is not the most generous with respect to shareholders' compensation.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
BIOTEST AG Stock Biotest AG
-7.47% 1.48B -
CSL LIMITED Stock CSL Limited
-4.06% 86.13B
A-
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+1.32% 39.82B
A-
UCB Stock UCB
+56.59% 25.23B
A
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-15.06% 15.36B
C
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.14% 11.95B
D+
INCYTE CORPORATION Stock Incyte Corporation
-16.59% 11.6B
B-
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-43.00% 11.51B
B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+6.44% 8.71B
B+
INNOVENT BIOLOGICS, INC. Stock Innovent Biologics, Inc.
-7.02% 8.12B
B-
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
-
  1. Stock Market
  2. Equities
  3. BIO3 Stock
  4. BIO3 Stock
  5. Ratings Biotest AG